Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Gastroenterol Hepatol ; 39(9): 590-596, 2016 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-27112800

RESUMO

INTRODUCTION: Variceal upper gastrointestinal bleeding (UGIB) can trigger acute hypoxic hepatitis (AHH). The aim of this study was to analyse the incidence, associated risk factors and mortality of AHH after variceal UGIB. PATIENTS AND METHODS: Retrospective study of cirrhotic patients with variceal UGIB, classified into 2 groups according to the development of AHH. AHH was diagnosed when AST and ALT reached levels 10 times above the upper limit of normal, after ruling out other causes of hepatitis. The standard initial treatment consisted of haemodynamic support, emergency endoscopy with rubber band ligation, somatostatin and antibiotics. In the case of failure of primary haemostasis, a transjugular intrahepatic portosystemic shunt (TIPS) was implanted. Both groups (AHH and non-AHH) were compared. RESULTS: Sixty-eight cirrhotic patients with variceal UGIB admitted to the gastroenterology department of Hospital Ramón y Cajal between January 2007 and March 2012 were analysed. Eleven of these patients (16.2%) developed AHH. Univariate analysis showed the following items as risk factors: diabetes (OR: 7.5; CI: 1.9-29), shock (OR: 8.5; CI: 2.06-34) and persistent bleeding (OR: 9.0, CI: 1.6-49, P=.03). However, multivariate analysis confirmed only diabetes (OR: 8.61; CI: 1.4-52.5) and shock (OR: 7.58; CI: 1.26-45.51) as risk factors. Mortality rate in the AHH group was 45%, compared to 10.5% in the non-HAA group (P=.012). CONCLUSIONS: AHH after variceal UGIB occurred in 16.2% of cirrhotic patients and was associated with a poorer prognosis, with a mortality rate of 45%. Our findings suggest that diabetes and shock are risk factors for the development of AHH. Early identification of at-risk patients could therefore help prevent AHH.


Assuntos
Varizes Esofágicas e Gástricas/complicações , Hemorragia Gastrointestinal/complicações , Isquemia/etiologia , Fígado/irrigação sanguínea , Adulto , Idoso , Carcinoma Hepatocelular/epidemiologia , Comorbidade , Complicações do Diabetes/epidemiologia , Feminino , Humanos , Isquemia/mortalidade , Hepatopatias Alcoólicas/epidemiologia , Neoplasias Hepáticas/epidemiologia , Masculino , Pessoa de Meia-Idade , Veia Porta , Recidiva , Estudos Retrospectivos , Fatores de Risco , Trombose/epidemiologia
2.
Gastroenterol Hepatol ; 36(4): 274-9, 2013 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-23522394

RESUMO

Acute hypertriglyceridemic pancreatitis is the third cause of acute pancreatitis in the Western population. There is usually an underlying alteration in lipid metabolism and a secondary factor. Clinical presentation is similar to that of pancreatitis of other etiologies, but the course of acute hypertriglyceridemic pancreatitis seems to be worse and more recurrent. Some laboratory data can be artefacts, leading to diagnostic errors. This is the case of amylase, which can show false low levels. Treatment is based on intense fluidotherapy and analgesia. When there is no response to conservative management, other methods to lower triglyceride levels should be used. Several options are available, such as plasmapheresis, insulin, and heparin. The present article provides a review of the current literature on this entity.


Assuntos
Hipertrigliceridemia/complicações , Pancreatite/etiologia , Dor Abdominal/etiologia , Doença Aguda , Alcoolismo/complicações , Amilases/sangue , Complicações do Diabetes , Erros de Diagnóstico , Suscetibilidade a Doenças , Reações Falso-Negativas , Feminino , Hidratação , Alimentos Formulados , Heparina/uso terapêutico , Humanos , Hiperlipoproteinemia Tipo IV/complicações , Hipertrigliceridemia/sangue , Hipertrigliceridemia/terapia , Insulina/uso terapêutico , Lipoproteínas LDL/sangue , Náusea/etiologia , Obesidade/complicações , Pancreatite/diagnóstico , Pancreatite/terapia , Plasmaferese , Gravidez , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/terapia , Sódio/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA